A growing portfolio of NNMT inhibitors, including substrate-competitive and bisubstrate-mimetic chemotypes, demonstrates nanomolar enzymatic potency and on-target activity in preclinical models, with early evidence for anti-tumor and chemosensitizing effects that could be exploited in CRC treatment. This evidence concerns the gene NNMT and colorectal carcinoma.